Matuzumab

• Description:

  Matuzumab (EMD 72000) is a humanized anti-EGFR monoclonal antibody that blocks EGFR activation and downstream signaling, inhibits tumor growth. Deglycosylation and the possible elimination of ADCC activity can reduce the in vivo anti-tumor activity of Mattuzumab[1].

• Product Name Alternative:

  EMD 72000

• UNSPSC:

  12352203

• Target:

  EGFR

• Type:

  Inhibitory Antibodies

• Related Pathways:

  JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/matuzumab.html

• Purity:

  99.0

• Solubility:

  H2O

• Smiles:

  [Matuzumab]

• Molecular Weight:

  (145.5 kDa)

• References & Citations:

  [1]Joan H Schiller. Developments in epidermal growth factor receptor-targeting therapy for solid tumors: focus on matuzumab (EMD 72000) . Cancer Invest. 2008 Feb;26 (1) :81-95.|[2]Bier H, et al. Anti- (epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol Immunother. 1998 May;46 (3) :167-73.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  Store at -80°C for 2 years

• Scientific Category:

  Inhibitory Antibodies

• Clinical Information:

  Phase 2

• CAS Number:

  [339186-68-4]